INTRODUCTION
Secukinumab, a human monoclonal antibody that selectively binds to and neutralizes interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis in the United States and Europe. In phase 3 studies, the efficacy of secukinumab has been demonstrated based on significant improvements in Psoriasis Area and Severity Index (PASI) responses compared with placebo, etanercept, and ustekinumab [1] [2] [3] [4] .
Although PASI is infrequently used in clinical practice, an improvement from Baseline of at least 75% (PASI 75) is well established in clinical trials as a clinically meaningful reduction in disease severity that also correlates with improvements in patients' quality of life [5] . As PASI includes separate assessments for psoriasis signs (erythema, thickening, and scaling) on the head and neck, trunk (including the genitals), upper limbs, and lower limbs [5] , PASI results can be adequately used to assess the effects of treatment on specific body regions. It is important to evaluate improvements in psoriasis on different body regions as psoriasis, on certain areas, disproportionately impacts quality of life [6, 7] . Accordingly, patients' perceived improvement and satisfaction with treatment may be differently impacted based on the areas where improvement occurs.
In this issue of Dermatology and Therapy, Kircik et al. reported the robust and sustained clearance of psoriatic lesions on the head and neck following treatment with secukinumab 300 mg and secukinumab 150 mg in a pooled population from four phase 3 trials [8] . Here we present the efficacy of secukinumab (300 or 150 mg), on the trunk, upper limbs, and lower limbs from the same pooled population, using PASI 90 and PASI 100 response rates. These levels of improvement have become the new benchmarks for success in treating patients with moderate-to-severe psoriasis, especially with new biologic agents [9] .
METHODS

Study Design
Pooled data to Week 52 from four phase 3, randomized, placebo-controlled, 
Efficacy Assessments
In all 4 trials, the coprimary efficacy variables
were PASI 75 response rates and IGA mod 2011
0\1 response rates at Week 12. The proportion of patients achieving PASI 90 at Week 12 was a key secondary endpoint in all trials.
Statistical Analysis
Efficacy data from the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials were pooled through Week 52. Missing values were imputed by multiple imputation (MI). The SAS (version 9.3, SAS Institute, Cary, NC, USA) MI procedure was used to generate data sets for 500
imputations. The MI method was used in this study because it more accurately reflects real world response rates than the non-responder imputation method, which underestimates PASI responses [11] . This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Patient Demographics
Of the 2403 randomized patients, the number eligible for the evaluation of each body region (PASI score C12 for that specific body region and psoriasis covering C10% of the surface area of that region) who received secukinumab were 1092 for the trunk, 1233 for the upper limbs, and 1309 for the lower limbs. As reported by Kircik et al. [8] , demographic characteristics for the pooled population were well balanced across secukinumab treatment groups [8] . More rapid responses were observed with the treatment of secukinumab 300 mg compared with secukinumab 150 mg across all body regions. The time to a 50% mean reduction in PASI subscore was quickest with secukinumab 300 mg for the head and neck region (2.0 weeks) [8] , followed by the trunk (2.8 weeks), upper limbs (2.9 weeks), and lower limbs (3.4 weeks). A similar trend was reported for secukinumab 150 mg, with the time to a 50% mean reduction in PASI subscore occurring first in the head and neck region (2.7 weeks) [8] followed by the trunk (3.4 weeks), upper limbs (3.7 weeks), and lower limbs (4.5 weeks). Additionally, in ERASURE and FIXTURE, improvement in PASI scores were mirrored by significant improvements in patient-reported symptoms of itching, pain, and scaling compared with placebo up to Week 12 as recorded by the Psoriasis Symptom DiaryÓ [12] . A limitation of this study is the lack of a control group after Week 12. Safety findings for the pooled population used in this analysis are reported separately by Kircik et al. [8] . Briefly, adverse events were observed at a similar rate between both secukinumab doses, and the most common adverse events through Week 52 were nasopharyngitis and headache.
Findings from this study are consistent with results from other studies that evaluated treatment efficacy by body region. In these studies, as well as in clinical practice, it has been observed that biologic treatment response typically starts on the head and upper body and progresses downward to lower body regions and extremities [13, 14] . For example, after 16 weeks of treatment with the tumor necrosis factor-alpha inhibitor adalimumab, the greatest PASI 100 subscore response rates were reported on the head and neck (55.7%) and the trunk (49.1%) compared with the upper limbs (33.3%) and the lower limbs (30.6%) [14] .
CONCLUSION
In conclusion, the results of our pooled analysis demonstrated that, on the trunk, upper limbs, and lower limbs, secukinumab-especially 300 mg-provided PASI 75, PASI 90, and PASI 100 subscore improvements that were rapid and sustained. Disease clearance occurred rapidly on highly visible areas of the skin, which is likely to produce a significant emotional improvement for patients. This study, and the accompanying article by Kircik et al. [8] , demonstrate the 
